Trial · NCT01514864
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival | Dasatinib, 140 mg (NSCLC With Inactivating B-RAF Mutation) | 3.06 | 90% Confidence Interval 0.76 to 6.47 | Months | |
| Overall Survival | Dasatinib, 140 mg (NSCLC With DDR2 Mutation) | 4.21 | 90% Confidence Interval 0.82 to NA | Months | |
| Progression-free Survival (PFS) Distribution | Dasatinib, 140 mg (NSCLC With Inactivating B-RAF Mutation) | 1.41 | 90% Confidence Interval 0.72 to 1.87 | Percentage of participants | |
| Progression-free Survival (PFS) Distribution | Dasatinib, 140 mg (NSCLC With DDR2 Mutation) | 1.38 | 90% Confidence Interval 0.59 to 2.96 | Percentage of participants | |
| Progression-free Survival (PFS) | Dasatinib, 140 mg (NSCLC With Inactivating B-RAF Mutation) | 1.41 | 90% Confidence Interval 0.72 to 1.87 | Months | |
| Progression-free Survival (PFS) | Dasatinib, 140 mg (NSCLC With DDR2 Mutation) | 1.38 | 90% Confidence Interval 0.59 to 2.96 | Months | |
| Number of Patients With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, and Drug-related AEs Leading to Discontinuation | Dasatinib, 140 mg (NSCLC With Inactivating B-RAF Mutation) | Death | 8 | Participants | |
| Number of Patients With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, and Drug-related AEs Leading to Discontinuation | Dasatinib, 140 mg (NSCLC With DDR2 Mutation) | Death | 4 | Participants | |
| Number of Patients With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, and Drug-related AEs Leading to Discontinuation | Dasatinib, 140 mg (NSCLC With Inactivating B-RAF Mutation) | Death within 30 days of last treatment | 3 | Participants | |
| Number of Patients With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, and Drug-related AEs Leading to Discontinuation | Dasatinib, 140 mg (NSCLC With DDR2 Mutation) | Death within 30 days of last treatment | 1 | Participants | |
| Number of Patients With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, and Drug-related AEs Leading to Discontinuation | Dasatinib, 140 mg (NSCLC With Inactivating B-RAF Mutation) | SAEs | 7 | Participants | |
| Number of Patients With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, and Drug-related AEs Leading to Discontinuation | Dasatinib, 140 mg (NSCLC With DDR2 Mutation) | SAEs | 4 | Participants | |
| Number of Patients With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, and Drug-related AEs Leading to Discontinuation | Dasatinib, 140 mg (NSCLC With Inactivating B-RAF Mutation) | Drug-related SAEs | 0 | Participants | |
| Number of Patients With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, and Drug-related AEs Leading to Discontinuation | Dasatinib, 140 mg (NSCLC With DDR2 Mutation) | Drug-related SAEs | 1 | Participants | |
| Number of Patients With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, and Drug-related AEs Leading to Discontinuation | Dasatinib, 140 mg (NSCLC With Inactivating B-RAF Mutation) | AEs leading to discontinuation | 7 | Participants | |
| Number of Patients With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, and Drug-related AEs Leading to Discontinuation | Dasatinib, 140 mg (NSCLC With DDR2 Mutation) | AEs leading to discontinuation | 2 | Participants | |
| Number of Patients With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, and Drug-related AEs Leading to Discontinuation | Dasatinib, 140 mg (NSCLC With Inactivating B-RAF Mutation) | Drug-related AEs leading to discontinuation | 2 | Participants | |
| Number of Patients With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, and Drug-related AEs Leading to Discontinuation | Dasatinib, 140 mg (NSCLC With DDR2 Mutation) | Drug-related AEs leading to discontinuation | 0 | Participants | |
| Number of Patients With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, and Drug-related AEs Leading to Discontinuation | Dasatinib, 140 mg (NSCLC With Inactivating B-RAF Mutation) | Drug-related AEs | 6 | Participants | |
| Number of Patients With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, and Drug-related AEs Leading to Discontinuation | Dasatinib, 140 mg (NSCLC With DDR2 Mutation) | Drug-related AEs | 3 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01514864/results